The target landscape of clinical kinase drugs-Reference-Cited by-同舟云学术

The target landscape of clinical kinase drugs

Published:2017-12 Issue:6367 Volume:358 Page:
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Klaeger Susan¹²³^ORCID,Heinzlmeir Stephanie¹²³^ORCID,Wilhelm Mathias¹^ORCID,Polzer Harald²³⁴,Vick Binje²³⁵^ORCID,Koenig Paul-Albert⁶^ORCID,Reinecke Maria¹²³,Ruprecht Benjamin¹,Petzoldt Svenja¹²³,Meng Chen¹,Zecha Jana¹²³,Reiter Katrin²³⁴^ORCID,Qiao Huichao¹,Helm Dominic¹^ORCID,Koch Heiner¹²³,Schoof Melanie¹,Canevari Giulia⁷,Casale Elena⁷,Depaolini Stefania Re⁷,Feuchtinger Annette⁸,Wu Zhixiang¹^ORCID,Schmidt Tobias¹^ORCID,Rueckert Lars⁹,Becker Wilhelm⁹^ORCID,Huenges Jan⁹,Garz Anne-Kathrin²³¹⁰,Gohlke Bjoern-Oliver²³¹¹^ORCID,Zolg Daniel Paul¹,Kayser Gian¹²^ORCID,Vooder Tonu¹³¹⁴¹⁵^ORCID,Preissner Robert²³¹¹,Hahne Hannes¹,Tõnisson Neeme¹⁴¹⁵^ORCID,Kramer Karl¹,Götze Katharina²³¹⁰,Bassermann Florian²³¹⁰^ORCID,Schlegl Judith¹⁶^ORCID,Ehrlich Hans-Christian⁹^ORCID,Aiche Stephan⁹^ORCID,Walch Axel⁸,Greif Philipp A.²³⁴,Schneider Sabine¹⁷¹⁸^ORCID,Felder Eduard Rudolf⁷^ORCID,Ruland Juergen²³⁶^ORCID,Médard Guillaume¹^ORCID,Jeremias Irmela²⁵¹⁹,Spiekermann Karsten²³⁴^ORCID,Kuster Bernhard¹²³¹⁸²⁰^ORCID

Affiliation:

1. Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

2. German Cancer Consortium (DKTK), Heidelberg, Germany.

3. German Cancer Research Center (DKFZ), Heidelberg, Germany.

4. Department of Internal Medicine III, University Hospital, Ludwig-Maximilians-Universität (LMU) München, Munich, Germany.

5. Department of Apoptosis in Hematopoietic Stem Cells, Helmholtz Center Munich, German Center for Environmental Health (HMGU), Munich, Germany.

6. Institut für Klinische Chemie und Pathobiochemie, TUM, Munich, Germany.

7. Oncology, Nerviano Medical Sciences Srl, Milan, Italy.

8. Research Unit Analytical Pathology, Helmholtz Zentrum München, Neuherberg, Germany.

9. SAP SE, Potsdam, Germany.

10. Department of Medicine III, Klinikum rechts der Isar, TUM, Munich, Germany.

11. Structural Bioinformatics Group, Charité-Universitätsmedizin, Berlin, Germany.

12. Institute of Surgical Pathology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

13. Center of Thoracic Surgery, Krefeld, Germany.

14. Estonian Genome Center, University of Tartu, Tartu, Estonia.

15. Tartu University Hospital, Tartu, Estonia.

16. SAP SE, Walldorf, Germany.

17. Department of Chemistry, TUM, Garching, Germany.

18. Center For Integrated Protein Science Munich (CIPSM), Munich, Germany.

19. Department of Pediatrics, Dr von Hauner Children’s Hospital, LMU, Munich, Germany.

20. Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), TUM, Freising, Germany.

Abstract

An atlas for drug interactions Kinase inhibitors are an important class of drugs that block certain enzymes involved in diseases such as cancer and inflammatory disorders. There are hundreds of kinases within the human body, so knowing the kinase “target” of each drug is essential for developing successful treatment strategies. Sometimes clinical trials can fail because drugs bind more than one target. Yet sometimes off-target effects can be beneficial, and drugs can be repurposed for treatment of additional diseases. Klaeger et al. performed a comprehensive analysis of 243 kinase inhibitors that are either approved for use or in clinical trials. They provide an open-access resource of target summaries that could help researchers develop better drugs, understand how existing drugs work, and design more effective clinical trials. Science , this issue p. eaan4368

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference123 articles.

1. FDA-approved small-molecule kinase inhibitors

2. Ten things you should know about protein kinases: IUPHAR Review 14

3. A quantitative analysis of kinase inhibitor selectivity

4. A broad activity screen in support of a chemogenomic map for kinase signalling research and drug discovery

5. Comprehensive analysis of kinase inhibitor selectivity

Cited by 647 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comprehensive detection and characterization of human druggable pockets through binding site descriptors;Nature Communications;2024-09-10

2. Kinase Drug Discovery: Impact of Open Science and Artificial Intelligence;Molecular Pharmaceutics;2024-09-06

3. Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors;European Journal of Medicinal Chemistry;2024-09

4. Proteomic approaches for protein kinase substrate identification in Apicomplexa;Molecular and Biochemical Parasitology;2024-09

5. Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity;European Journal of Medicinal Chemistry;2024-09